CADL Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

-0.252

-37.05%

-0.210

-261.54%

-0.210

+133.33%

Estimates Revision

The market is revising No Change the revenue expectations for Candel Therapeutics, Inc. (CADL) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -7.75%.

EPS Estimates for FY2025

Revise Upward

+17.93%

In Past 3 Month

Stock Price

Go Down

-7.75%

In Past 3 Month

6 Analyst Rating

Wall Street analysts forecast CADL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CADL is 18.33 USD with a low forecast of 7.00 USD and a high forecast of 25.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

5 Buy

1 Hold

0 Sell

Strong Buy

Current: 0.000

Low

7.00

Averages

18.33

High

25.00

Current: 0.000

Low

7.00

Averages

18.33

High

25.00

Citi

Yigal Nochomovitz

Buy

downgrade

$25 -> $24

2025-11-14

Reason

Citi

Yigal Nochomovitz

Price Target

$25 -> $24

2025-11-14

downgrade

Buy

Reason

Citi analyst Yigal Nochomovitz lowered the firm's price target on Candel Therapeutics to $24 from $25 and keeps a Buy rating on the shares.

Stephens

Overweight

initiated

$15

2025-10-28

Reason

Stephens

Price Target

$15

2025-10-28

initiated

Overweight

Reason

As previously reported, Stephens initiated coverage of Candel Therapeutics with an Overweight rating and $15 price target. Though financing and market penetration remain "open questions," the company's pipeline represents "a differentiated and potentially transformative entry" within next-generation therapeutic modalities with lead asset CAN-2409 functioning as an augmentative therapy designed to complement, rather than replace, existing standards of care, which the firm sees limiting competitive pressures and allowing for broad application across multiple indications.

Stephens

initiated

$15

2025-10-27

Reason

Stephens

Price Target

$15

2025-10-27

initiated

Reason

Stephens initiated coverage of Candel Therapeutics with an Overweight rating and $15 price target.

LifeSci Capital

initiated

$16

2025-10-21

Reason

LifeSci Capital

Price Target

$16

2025-10-21

initiated

Reason

LifeSci Capital initiated coverage of Candel Therapeutics with an Outperform rating and $16 price target.

BofA

Buy -> Neutral

downgrade

2025-09-03

Reason

BofA

Price Target

2025-09-03

downgrade

Buy -> Neutral

Reason

BofA downgraded Candel Therapeutics to Neutral from Buy with a $7 price target.

BofA

Buy -> Neutral

downgrade

$13 -> $7

2025-09-03

Reason

BofA

Price Target

$13 -> $7

2025-09-03

downgrade

Buy -> Neutral

Reason

As previously reported, BofA downgraded Candel Therapeutics to Neutral from Buy with a price target of $7, down from $13. The firm sees catalyst flow picking up for its small-to-mid sized biotech coverage heading into early 2026, but would deprioritize stocks without near-term catalysts given the environment it would argue \"has been more rewarding for positive clinical data than in recent years.\" For Candel in particular, the firm sees \"a relative catalyst desert\" until a BLA filing in Q4 of 2026 and views pipeline development as likely conditional on additional financing, the analyst tells investors.

Valuation Metrics

The current forward P/E ratio for Candel Therapeutics Inc (CADL.O) is -6.10, compared to its 5-year average forward P/E of -5.04. For a more detailed relative valuation and DCF analysis to assess Candel Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-5.04

Current PE

-6.10

Overvalued PE

-1.69

Undervalued PE

-8.38

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-2.70

Current EV/EBITDA

-4.03

Overvalued EV/EBITDA

0.39

Undervalued EV/EBITDA

-5.79

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

634.88

Current PS

0.00

Overvalued PS

1601.77

Undervalued PS

-332.02

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

CADL News & Events

Events Timeline

No data

News

1.0

2025-11-17Newsfilter

Candel Therapeutics to Hold Online R&D Event on December 5, 2025

4.0

2025-11-15NASDAQ.COM

Citigroup Upholds Buy Rating for Candel Therapeutics (CADL)

9.0

2025-11-14SeekingAlpha

Candel Halts Development of CAN-2409 for Prostate Cancer

People Also Watch

Frequently Asked Questions

What is Candel Therapeutics Inc (CADL) stock price today?

The current price of CADL is 5.71 USD — it has increased 2.88 % in the last trading day.

What is Candel Therapeutics Inc (CADL)'s business?

Candel Therapeutics, Inc. is a BLA-ready clinical-stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic antitumor immune response to help patients fight cancer. CAN-2409 is the lead product candidate from the adenovirus platform. CAN-3110 is the lead product candidate from the herpes simplex virus (HSV) platform and is in an ongoing phase Ib clinical trial in recurrent high-grade glioma. Its enLIGHTEN Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. CAN-2409, Its advanced multimodal biological immunotherapy candidate, is an investigational, off-the-shelf, replication-defective adenovirus engineered to deliver the herpes simplex virus thymidine kinase (HSV-tk) gene to a patient’s specific tumor and induce an individualized, systemic immune response against the tumor.

What is the price predicton of CADL Stock?

What is Candel Therapeutics Inc (CADL)'s revenue for the last quarter?

Candel Therapeutics Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

What is Candel Therapeutics Inc (CADL)'s earnings per share (EPS) for the last quarter?

Candel Therapeutics Inc. EPS for the last quarter amounts to -0.21 USD, decreased -36.36 % YoY.

What changes have occurred in the market's expectations for Candel Therapeutics Inc (CADL)'s fundamentals?

How many employees does Candel Therapeutics Inc (CADL). have?

Candel Therapeutics Inc (CADL) has 38 emplpoyees as of January 11 2026.

What is Candel Therapeutics Inc (CADL) market cap?

Today CADL has the market capitalization of 313.47M USD.